- Details
- Oliver Sartor joins Charles Ryan to talk about the VISION trial, a trial testing the PSMA-617 agent, The novel therapeutic drug 177Lu-PSMA-617 is a prostate-specific membrane antigen (PSMA) targeting agent to deliver radionuclide therapy for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The primary objective of this study is to compare the 2 alternative en...
|
- Details
- At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 meeting, Stefano Fanti presented the advantages of PSMA PET-CT in advanced prostate cancer imaging. He highlighted the role of PSMA PET-CT in staging, biochemical recurrence, and therapy planning. Biography: Stefano Fanti, MD, Professor, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, Director of Nuclear Medic...
|
- Details
- Professor Ian Davis joins Carmel Pezaro to discuss the pitfalls of PSMA PET CT scans at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Starting the discussion on the disadvantages of PSMA PET, Professor Davis refers to PSMA PET as a bit of a mixed blessing and the challenge being the amount of enthusiasm for it and trying to bring it into clinical practice in a meaningful way. Wit...
|
- Details
- (Length of Interview: 14 min) John Fortin interviews Art Rastinehad on a new publication published in the Proceedings of the National Academy of Science on prostate cancer and nanomedicine. Art Rastinehad and colleagues at Icahn Scool of Medicine at Mount Sinai are the first to perform human trials using nanoshell directed photothermal ablation. In this podcast interview, Dr. Rastinehad reports th...
|
- Details
- Anwar Padhani presents at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 on imaging and flare responses when assessing patients with metastatic castration-resistant prostate cancer (mCRPC). In his presentation, Dr. Padhani notes that bone scans/CT scans lead to poor confidence for knowing the true clinical states and assessing therapy benefits for bone disease in advanced prostate...
|
- Details
- Michael Morris, MD, and Larry (Lawrence) Schwartz joins Charles Ryan, MD in a conversation about credentialing imaging as an outcome measure in prostate cancer and its impact in clinical trials. They focus on the following questions: How do we credential images? How do we perform them? And how do we interpret them? Their conversation also focuses on determining progression-free survival (PFS) from...
|
- Details
- The Society of Nuclear Medicine and Molecular Imaging (SNMMI) presents the Prostate Cancer Imaging and Therapy curriculum. In this continuing education session, Dr. Ephraim Parent joins Dr. Phil Koo to present and discuss bone imaging and the role in prostate cancer, specifically bone scintigraphy. His presentation outlines an overview of Radiopharmaceuticals that are used for bone imaging, planar...
|
- Details
- Frankis Almaguel, MD joins Phillip Koo, MD for the ongoing lecture series that is sponsored by the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Dr. Almaguel speaks to therapeutic interventions based on Prostate-specific membrane antigen (PSMA) findings that have the potential of changing the treatment of prostate cancer and the impact of personalized care in this disease space. Frank...
|
- Details
- The Society of Nuclear Medicine and Molecular Imaging (SNMMI) presents the Prostate Cancer Imaging and Therapy curriculum. Dr. Andrei Iagaru presents the state of development of Gastrin-Releasing Peptide Receptors as Targets for Imaging in Prostate Cancer. He and Phil Koo, MD then discuss the clinical development of Bombesin in the imaging of prostate cancer. Biographies: Andrei H. Iagaru, MD, FAC...
|
- Details
- Misha Beltran shares details on the Department of Defense grant, a collaboration with Scott Tagawa and Neil Bander at Weill Cornell, and now a continuing effort at the Dana-Farber Cancer Institute. This grant is providing funding to really hone in on the therapeutic side of who are the patients most likely to benefit from PSMA scanning. Focusing on better treatment options for these patients and w...
|
